Sugi Predict

Sugi Predict / Compounds / SCHEMBL19085535

SCHEMBL19085535

SCHEMBL19085535

CC(=O)NCCc1ccc(NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 1/20 0.57
▸ KDM4E B2RXH2 2/20 0.54
▸ F13A1 P00488 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ CYP17A1 P05093 2/20 0.53
▸ DRD2 P14416 1/20 0.50
▸ CNR1 P21554 2/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ PTGS1 P23219 1/20 0.47
▸ BLM P54132 1/20 0.47
▸ HIF1A Q16665 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ CA2 P00918 2/20 0.46
▸ CA1 P00915 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ ACACB O00763 1/20 0.46
▸ PTGDR2 Q9Y5Y4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15359144 0.88 NAMPT (0.54) NAMPTCYP17A1DRD2CNR1LMNA
SCHEMBL16523129 0.85 CYP17A1 (0.56) NAMPTCYP17A1DRD2MAPTPTGDR2
SCHEMBL15359140 0.84 NAMPT (0.53) NAMPTCYP17A1DRD2CNR1CA2
SCHEMBL580319 0.83 NAMPT (0.57) NAMPTSMN1; SMN2CNR1ALDH1A1LMNA
SCHEMBL12677009 0.82 CYP17A1 (0.58) NAMPTCYP17A1DRD2ALDH1A1HPGD
SCHEMBL16246084 0.82 CYP17A1 (0.58) NAMPTCYP17A1DRD2HPGDCA1
SCHEMBL27493682 0.82 CYP17A1 (0.58) NAMPTCYP17A1DRD2HPGDCA1
SCHEMBL2244813 0.82 CYP17A1 (0.58) NAMPTCYP17A1DRD2PTGDR2MAPK14
SCHEMBL16193024 0.82 NAMPT (0.62) NAMPTSMN1; SMN2CYP17A1ALDH1A1LMNA
SCHEMBL14431407 0.81 KDM4E (0.68) KDM4EF13A1SMN1; SMN2CNR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540219-B2 Method for deacetylation of biopolymers Galderma Holding SA (CH) 2026-02-03 — — US disclosed
US-12365768-B2 Method for deacetylation of biopolymers Galderma Holding SA (CH) 2025-07-22 — — US disclosed
EP-3397650-B1 HYDROLYSIS OF ESTER BONDS IN AMIDE CROSSLINKED GLYCOSAMINOGLYCANS GALDERMA SA (CH) 2025-05-14 — — EP disclosed
US-20240199822-A1 METHOD FOR PREPARING ACYLATED CROSSLINKED GLYCOSAMINOGLYCANS Galderma Holding SA (CH) 2024-06-20 — — US disclosed
US-11939433-B2 Method for preparing acylated crosslinked glycosaminoglycans GALDERMA HOLDING S.A. (CH) 2024-03-26 — — US disclosed
US-20230323041-A1 METHOD FOR PREPARING ACYLATED CROSSLINKED GLYCOSAMINOGLYCANS Galderma Holding SA (CH) 2023-10-12 — — US disclosed
US-20230323041-A1 METHOD FOR PREPARING ACYLATED CROSSLINKED GLYCOSAMINOGLYCANS Galderma Holding SA (CH) 2023-10-12 — — US disclosed
US-20230323041-A1 METHOD FOR PREPARING ACYLATED CROSSLINKED GLYCOSAMINOGLYCANS Galderma Holding SA (CH) 2023-10-12 — — US disclosed
US-11708461-B2 Method for preparing acylated crosslinked glycosaminoglycans Galderma Holding SA (CH) 2023-07-25 — — US disclosed
US-11708461-B2 Method for preparing acylated crosslinked glycosaminoglycans Galderma Holding SA (CH) 2023-07-25 — — US disclosed
CN-109641975-A Method for cracking amido bond 高德美股份公司 2019-04-16 — — CN disclosed
US-20190023855-A1 HYDROLYSIS OF ESTER BONDS IN AMIDE CROSSLINKED GLYCOSAMINOGLYCANS GALDERMA S.A. (CH) 2019-01-24 — — US disclosed
US-20190016830-A1 METHOD FOR DEACETYLATION OF BIOPOLYMERS GALDERMA S.A. (CH) 2019-01-17 — — US disclosed
CN-108884173-A METHOD FOR CLEAVING AMIDE BONDS 高德美股份公司 2018-11-23 — — CN disclosed
CN-108779184-A Method for deacetylation of biopolymers 高德美股份公司 2018-11-09 — — CN disclosed
WO-2017207564-A1 METHOD FOR CLEAVING AMIDE BONDS GALDERMA S.A. (CH) 2017-12-07 — — WO disclosed
WO-2017114859-A1 METHOD FOR CLEAVING AMIDE BONDS GALDERMA S.A. (CH) 2017-07-06 — — WO disclosed
WO-2017114865-A1 HYDROLYSIS OF ESTER BONDS IN AMIDE CROSSLINKED GLYCOSAMINOGLYCANS GALDERMA S.A. (CH) 2017-07-06 — — WO disclosed
WO-2017114861-A1 METHOD FOR DEACETYLATION OF BIOPOLYMERS GALDERMA S.A. (CH) 2017-07-06 — — WO disclosed
WO-2017114864-A1 METHOD FOR PREPARING ACYLATED CROSSLINKED GLYCOSAMINOGLYCANS GALDERMA S.A. (CH) 2017-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11939433-B2 Method for preparing acylated crosslinked glycosaminoglycans ALG1, CSGALNACT1, AMDHD2 NAMPT 1160/4885KDM4E 1217/4885F13A1 75/4885
US-20240199822-A1 METHOD FOR PREPARING ACYLATED CROSSLINKED GLYCOSAMINOGLYCANS ALG1, CSGALNACT1, AMDHD2 NAMPT 1160/4885KDM4E 1217/4885F13A1 75/4885
US-12540219-B2 Method for deacetylation of biopolymers CA12, CA13, CA1 NAMPT 1519/4885KDM4E 1887/4885F13A1 86/4885
US-11708461-B2 Method for preparing acylated crosslinked glycosaminoglycans ALG1, CSGALNACT1, AMDHD2 NAMPT 1160/4885KDM4E 1217/4885F13A1 75/4885
US-20230323041-A1 METHOD FOR PREPARING ACYLATED CROSSLINKED GLYCOSAMINOGLYCANS ALG1, CSGALNACT1, AMDHD2 NAMPT 1160/4885KDM4E 1217/4885F13A1 75/4885
US-20190023855-A1 HYDROLYSIS OF ESTER BONDS IN AMIDE CROSSLINKED GLYCOSAMINOGLYCANS AMDHD2, HPSE, ENGASE NAMPT 995/4885KDM4E 1361/4885F13A1 387/4885
US-12365768-B2 Method for deacetylation of biopolymers AADAC, ALG1, AMDHD2 NAMPT 546/4885KDM4E 1592/4885F13A1 676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.